Abstract PS5-01-04: Clinical predictors for first-line treatment duration in HER2-positive metastatic breast cancer Results from the AGMTMBC-Registry

Abstract Background: Based upon the CLEOPATRA trial, a combination of docetaxel plus trastuzumab and pertuzumab (THP) has been the standard treatment for patients with metastatic HER2-positive breast cancer. However, this standard has recently been challenged by the results of the DESTINY-Breast09 study, which compared trastuzumab-deruxtecan (T-DXd) plus pertuzumab with THP. In this analysis, we aimed to develop a risk model based on known parameters that identifies patients with a long first-line (1L) therapy duration, as these patients may not need 1L T-DXd therapy. Patients and Methods: The AGMTMBC-Registry is a nationwide, multicenter, ongoing retrospective and prospective registry for metastatic breast cancer (MBC) patients in Austria. Patients with HER2-positive breast cancer treated with a 1L chemo, trastuzumab plus pertuzumab combination were included in this analysis. Time to next treatment (TTNT) was defined as the interval from initiation of 1L to the initiation of the next subsequent treatment line. To identify prognostic factors associated 1L TTNT a multivariable Cox proportional hazards model was performed. Clinical, demographic, and tumor-related covariates - including metastatic sites, age, hormone-receptor (HR) status, and tumor grade - were included in the analysis. Variable selection was performed using a bidirectional stepwise approach based on the Akaike Information Criterion. Patients with missing values were excluded. A risk score was derived from the linear predictor of the Cox model. Survival-optimized cut-off points were identified using maximally selected rank statistics to stratify patients into low-, intermediate-, and high-risk groups. Hazard ratios (HRs) with 95% confidence intervals (CIs) are reported. Time-to-event analyses were performed using Kaplan-Meier estimates, with group-specific survival probabilities reported at 12, 18, and 36 months. Results: As of March 11, 2025, the registry included 3, 094 patients, and 218 patients with HER2-positive MBC were available for this analysis. Median age at diagnosis of MBC was 58 years (range 26-85) and 62% had hormone receptor (HR) positive disease. Bone (57%), liver (43%), and lung metastases (35%) were the most common metastatic sites; brain, pleural, and peritoneal metastases were rare (5%). At diagnosis, 63% had de novo MBC, 31% had recurrence ≥24 months, and 6% 24 months after surgery. The final multivariable Cox model identified the presence of brain (HR 2. 22, p = 0. 038), pleural metastases (HR 3. 41, p = 0. 001), disease-free survival 24 months (HR 1. 98, p=0. 046), and older age (HR 1, 01 per year, p = 0. 043) as significant predictors for a shorter TTNT. Lung metastasis (HR 1. 36, p = 0. 089) showed a trend toward shorter treatment duration. Based on the risk score, patients were stratified into low- (27%, n = 56), intermediate- (62%, n = 127), and high-risk groups (10%, n = 21). Compared to the low-risk group, TTNT was shorter in the intermediate-risk group (HR 1. 79, 95% CI 1. 17-2. 74; p = 0. 007) and in the high-risk group (HR 5. 39, 95% CI 2. 95-9. 86; p 0. 001). In the high-risk group, treatment continuation rates were 45% (95% CI 28-73%) at 12 months, 17% at 18 months, and 6% at 36 months, respectively. In the intermediate-risk group, corresponding rates were 74% (95% CI 67-82%), 63%, and 36%; and in the low-risk group, 84% (95% CI 74-94%), 65%, and 50%, respectively. Conclusion: This real-world analysis identified distinct clinical subgroups of patients with HER2-positive MBC who are at low risk for early 1L treatment discontinuation under the current standard CLEOPATRA regimen. The proposed risk model enables prognostic stratification and may help identify patients who do or do not need an alternative 1L approach, such as T-DXd-based combinations. External validation of the score in independent cohorts is warranted. Citation Format: G. Rinnerthaler, S. P. Gampenrieder, A. Pichler, W. Herz, R. Pusch, C. Dormann, C. Suppan, M. Sandholzer, T. Winder, S. Heibl, L. Scagnetti, C. A. Schmitt, A. F. Zabernigg, D. Egle, C. Hager, P. Pichler, F. Roitner, J. Andel, K. Strasser-Weippl, R. Bartsch, V. Castagnaviz, M. Hubalek, M. Knauer, C. F. Singer, R. Greil. Clinical predictors for first-line treatment duration in HER2-positive metastatic breast cancer Results from the AGMTMBC-Registry abstract. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32 (4 Suppl): Abstract nr PS5-01-04.